Vaxcyte

Vaxcyte announces it will release Phase‑III data for the 31‑valent pneumococcal vaccine VAX‑31 by the end of October and plans an investor package and a conference call to accompany the release. Management points to the expected coverage of about 95% of circulating serotypes as an advantage over Prevnar 20 (≈60%) and CAPVAXIVE (≈80%), but warns of regulatory and competitive risks. Manufacturing, the build‑out of the commercial team and a fully recruited infant Phase‑II program are proceeding on schedule; the company is taking incremental steps to prepare for a potential market launch. » Więcej na de.investing.com

At the Wells Fargo conference, Vaxcyte presented a strategy aimed at broader serotype coverage and stronger immune responses. Lead candidate VAX-31 is in Phase III; the company said OPUS-1 data could be available by the end of October 2024 and is expected to show coverage of around 95% of circulating pneumococcal strains (Prevnar 20 about 60%, CAPVAXIVE around 82%). Vaxcyte cites Phase II data showing roughly a 25% higher average immune response and emphasizes its cell-free protein synthesis platform; VAX-A1 against group A streptococcus is in Phase I. The company is targeting approval by the end of 2028, contingent on manufacturing consistency, and expects OPUS-2/OPUS-3 results in the first half of 2025. » Więcej na de.investing.com

CEO Grant Pickering surrendered 6,289 Vaxcyte shares in a non‑discretionary transaction to cover tax withholdings on vested RSUs, leaving him with roughly 447,000 directly held shares and 266,430 indirectly held shares in trusts. Vaxcyte is preparing for topline OPUS-1 Phase 3 data on VAX-31 in the fourth quarter, a pivotal readout versus Pfizer and Merck that will determine filing timelines. The company reported high cash burn ($284.3m in the June quarter) but holds about $2.5bn in cash, making the trial outcome critical for its commercial prospects and cash runway. » Więcej na finance.yahoo.com